Positive News SentimentPositive NewsNASDAQ:KZR Kezar Life Sciences (KZR) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free KZR Stock Alerts $0.66 -0.02 (-2.92%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.66▼$0.7050-Day Range$0.68▼$0.8652-Week Range$0.65▼$2.61Volume304,153 shsAverage Volume651,760 shsMarket Capitalization$48.34 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Kezar Life Sciences alerts: Email Address Kezar Life Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,556.6% Upside$11.00 Price TargetShort InterestHealthy4.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.24) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsMedical Sector163rd out of 913 stocksPharmaceutical Preparations Industry66th out of 429 stocks 3.2 Analyst's Opinion Consensus RatingKezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Kezar Life Sciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.79% of the outstanding shares of Kezar Life Sciences have been sold short.Short Interest Ratio / Days to CoverKezar Life Sciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Kezar Life Sciences has recently decreased by 5.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kezar Life Sciences is -0.85. Previous Next 2.7 News and Social Media Coverage News SentimentKezar Life Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kezar Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for KZR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kezar Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.30% of the stock of Kezar Life Sciences is held by insiders.Percentage Held by Institutions67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kezar Life Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kezar Life Sciences are expected to decrease in the coming year, from ($1.24) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kezar Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Kezar Life Sciences Stock (NASDAQ:KZR)Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More KZR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZR Stock News HeadlinesJune 7, 2024 | businesswire.comKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)May 29, 2024 | businesswire.comKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceMay 16, 2024 | investing.comKezar Life Sciences Inc (KZR)May 10, 2024 | markets.businessinsider.comHold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy ConcernsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kezar Life Sciences Amid Promising Clinical Trials and Strong Financial PositionMay 9, 2024 | msn.comKZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024May 9, 2024 | businesswire.comKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | businesswire.comKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 8, 2024 | businesswire.comKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)March 27, 2024 | investorplace.comFrom Pennies to Fortunes: 3 Stocks Set to Make MillionairesMarch 16, 2024 | investorplace.comDiamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026March 14, 2024 | investorplace.comKZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023March 14, 2024 | businesswire.comKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | finanznachrichten.deEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for NefeconMarch 3, 2024 | finance.yahoo.comKezar Life Sciences, Inc. (KZR)February 28, 2024 | finance.yahoo.comKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese MarketFebruary 26, 2024 | businesswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 26, 2024 | prnewswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 22, 2024 | benzinga.comKezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and DatesFebruary 19, 2024 | thestreet.comKezar Life Sciences Inc.February 10, 2024 | finance.yahoo.com3 Penny Stocks Poised for an Unbelievable 1,000% JumpJanuary 31, 2024 | morningstar.comKezar Life Sciences Inc KZRJanuary 18, 2024 | finance.yahoo.comKZR Jan 2025 17.500 callSee More Headlines Receive KZR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/17/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KZR CUSIPN/A CIK1645666 Webwww.kezarlifesciences.com Phone(650) 822-5600FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+1,556.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,870,000.00 Net MarginsN/A Pretax Margin-1,447.56% Return on Equity-47.28% Return on Assets-40.79% Debt Debt-to-Equity Ratio0.05 Current Ratio11.48 Quick Ratio11.49 Sales & Book Value Annual Sales$7 million Price / Sales6.91 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.26Miscellaneous Outstanding Shares72,801,000Free Float66,031,000Market Cap$48.34 million OptionableNot Optionable Beta0.23 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Christopher J. Kirk Ph.D. (Age 52)Co-Founder, CEO & Director Comp: $644.68kMr. John Franklin Fowler (Age 52)Co-Founder & Director Comp: $539.35kMr. Marc L. Belsky (Age 69)CFO & Secretary Comp: $639.41kDr. Jack Taunton Ph.D.Co-FounderMs. Gitanjali JainVice President of Investor Relations & External AffairsMr. Mark Schiller (Age 44)Chief Legal Officer Mr. Joe TedrickVice President of Human ResourcesDr. Neel K. Anand Ph.D.Senior Vice President of Research & Drug DiscoveryMr. Zung ToSenior Vice President of Clinical DevelopmentMs. Pattie ChiangVP & Corporate ControllerMore ExecutivesKey CompetitorsNextCureNASDAQ:NXTCHookipa PharmaNASDAQ:HOOKZevra TherapeuticsNASDAQ:ZVRAGreenwich LifeSciencesNASDAQ:GLSIAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInstitutional OwnershipIkarian Capital LLCBought 15,601 shares on 5/17/2024Ownership: 1.194%Jacobs Levy Equity Management Inc.Sold 917,619 shares on 5/16/2024Ownership: 0.073%Affinity Asset Advisors LLCBought 1,761,778 shares on 5/15/2024Ownership: 2.420%Vanguard Group Inc.Bought 30,740 shares on 5/10/2024Ownership: 4.250%Acadian Asset Management LLCBought 534,203 shares on 5/10/2024Ownership: 2.460%View All Institutional Transactions KZR Stock Analysis - Frequently Asked Questions Should I buy or sell Kezar Life Sciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares. View KZR analyst ratings or view top-rated stocks. What is Kezar Life Sciences' stock price target for 2024? 3 Wall Street research analysts have issued twelve-month target prices for Kezar Life Sciences' stock. Their KZR share price targets range from $2.00 to $20.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,556.6% from the stock's current price. View analysts price targets for KZR or view top-rated stocks among Wall Street analysts. How have KZR shares performed in 2024? Kezar Life Sciences' stock was trading at $0.9474 at the start of the year. Since then, KZR stock has decreased by 29.9% and is now trading at $0.6640. View the best growth stocks for 2024 here. When is Kezar Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our KZR earnings forecast. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences, Inc. (NASDAQ:KZR) announced its earnings results on Thursday, May, 9th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.04. What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL). When did Kezar Life Sciences IPO? Kezar Life Sciences (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO. Who are Kezar Life Sciences' major shareholders? Kezar Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.25%), Acadian Asset Management LLC (2.46%), Affinity Asset Advisors LLC (2.42%), Ikarian Capital LLC (1.19%), BNP Paribas Financial Markets (0.38%) and Marquette Asset Management LLC (0.17%). Insiders that own company stock include Franklin M Berger, Michael Kauffman and Morningside Venture Investment. View institutional ownership trends. How do I buy shares of Kezar Life Sciences? Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KZR) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the...Porter & Company | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.